1591-99-7

Basic information

• Product Name: 2,3-DIMETHYLPHENYL ISOCYANATE
• Synonyms: 1-Isocyanato-2,3-dimethylbenzene;2,3-DIMETHYLPHENYL ISOCYANATE;2,3-Dimethyphenyl isocyanate;2,3-Dimethylphenyl isocyanate,99+%
• CAS NO: 1591-99-7
• Molecular Formula: C₉H₉NO
• Molecular Weight: 147.17
• Product Categories: Isocyanates;Nitrogen Compounds;Organic Building Blocks;Building Blocks;Chemical Synthesis;Nitrogen Compounds;Organic Building Blocks
• Mol File: 1591-99-7.mol
• Article Data: 5

Chemical Properties

• Boiling Point: 105 °C50 mm Hg(lit.)
• Flash Point: 199 °F
• Appearance: clear slightly yellow liquid
• Density: 1.059 g/mL at 25 °C(lit.)
• Vapor Pressure: 0.068mmHg at 25°C
• Refractive Index: n20/D 1.54(lit.)
• Sensitive: Moisture Sensitive
• BRN: 6313438
• CAS DataBase Reference: 2,3-DIMETHYLPHENYL ISOCYANATE(CAS DataBase Reference)
• NIST Chemistry Reference: 2,3-DIMETHYLPHENYL ISOCYANATE(1591-99-7)
• EPA Substance Registry System: 2,3-DIMETHYLPHENYL ISOCYANATE(1591-99-7)

Safety Data

• Hazard Codes: Xn
• Statements: 20/21/22-36/37/38
• Safety Statements: 26-36
• RIDADR: UN 2206 6.1/PG 3
• WGK Germany: 3
• HazardClass: 6.1
• PackingGroup: III
• Hazardous Substances Data: 1591-99-7(Hazardous Substances Data)

Usage

Uses

Used in Research Applications:
2,3-DIMETHYLPHENYL ISOCYANATE is used as a research reagent for [application reason] its unique chemical properties and reactivity, enabling scientists to explore new chemical reactions and mechanisms.
Used in Pharmaceutical Industry:
2,3-DIMETHYLPHENYL ISOCYANATE is used as a pharmaceutical intermediate for [application reason] its potential role in the synthesis of various pharmaceutical compounds, contributing to the development of new drugs and therapies.
Used in Organic Synthesis:
2,3-DIMETHYLPHENYL ISOCYANATE is used as an organic synthesis building block for [application reason] its ability to serve as a key component in the creation of complex organic molecules, facilitating the advancement of organic chemistry and the production of novel materials.

InChI:InChI=1/C9H9NO/c1-7-4-3-5-9(8(7)2)10-6-11/h3-5H,1-2H3

Upstream product

• 32315-10-9 bis(trichloromethyl) carbonate 
• 87-59-2 2,3-Dimethylaniline 

Downstream Products

• 50909-95-0 1-(2,3-Dimethyl-phenyl)-3-(1-methyl-1-p-tolyl-ethyl)-urea 
• 42609-71-2 1-(2,3-Dimethyl-phenyl)-3-(1-methyl-1-o-tolyl-ethyl)-urea 
• 50910-00-4 1-(2,3-Dimethyl-phenyl)-3-(1-methyl-1-m-tolyl-ethyl)-urea 
• 34203-74-2 C₂₁H₂₅N₃O₄ 
• 32496-34-7 (2,3-Dimethyl-phenyl)-carbamic acid 1-methyl-prop-2-ynyl ester 
• 32496-35-8 (2,3-Dimethyl-phenyl)-carbamic acid 1,1-dimethyl-prop-2-ynyl ester 
• 64393-16-4 1-Cyclopropyl-3-(2,3-dimethyl-phenyl)-harnstoff 
• 88451-10-9 1-Benzyl-1-butyl-3-(2,3-dimethyl-phenyl)-urea 
• 1261029-03-1 C₁₂H₁₅NO₂ 
• 20642-94-8 (2,3-Dimethyl-phenyl)-carbamic acid methyl ester 
• 1285533-86-9 4-[4-[[[[2,3-dimethylphenyl]amino]carbonyl]amino]phenoxy]-N-methylpyridine-2-carboxamide 
• 1423126-48-0 1-(4-((1H-pyrazolo[3,4-d]pyrimidin-4-yl)oxy)phenyl)-3-(2,3-dimethylphenyl)urea 
• 1423126-77-5 C₁₅H₁₆N₂O₂ 
• 67116-97-6 3-(2,3-dimethylphenyl)quinazoline-2,4(1H,3H)-dione 

Relevant articles and documents

Palladium(0)-catalyzed carbon-Hydrogen bond functionalization for the synthesis of indoloquinazolinones

The indoloquinazolinone ring system has attracted considerable attention as a pharmacophore, because it shows various biological activities. The reported synthetic methods for the compound are simple and direct, but are not effective for the direct synthesis of indoloquinazolinone with a methylene group at the C-6 position. A palladium(0)-catalyzed cyclization of chloroquinazolinone via C-H functionalization was developed for a concise synthesis of indoloquinazolinone derivatives. The presence of a substituent at the C-6 position is important for obtaining the product in good yield. The conformation of the reaction intermediate, in particular the N-C-Pd bond angle, is important for the regioselectivity of the reaction.

Structure-activity relationship studies of pyrazolo[3,4-d]pyrimidine derivatives leading to the discovery of a novel multikinase inhibitor that potently inhibits FLT3 and VEGFR2 and evaluation of its activity against acute myeloid leukemia in vitro and in vivo

We describe the structural optimization of a hit compound, 1-(4-(1H-pyrazolo[3,4-d]pyrimidin-4-ylamino)phenyl)-3-(3-methoxyphenyl)urea (1), which exhibits inhibitory activity but low potency against FLT3 and VEGFR2. A series of pyrazolo[3,4-d]pyrimidine derivatives were synthesized, and structure-activity relationship analysis using cell- and transgenic-zebrafish- based assays led to the discovery of a number of compounds that exhibited both high potency against FLT3-driven human acute myeloid leukemia (AML) MV4-11 cells and a considerable antiangiogenic effect in transgenic-zebrafish-based assays. The compound 1-(4-(1H-pyrazolo[3,4-d]pyrimidin -4-yloxy)phenyl)-3-(4-chloro-3- (trifluoromethyl)phenyl)urea (33), which exhibited the highest activity in preliminary in vivo anti-AML assays, was chosen for further anti-AML studies. The results demonstrated that compound 33 is a multikinase inhibitor that potently inhibits FLT3 and VEGFR2. In an MV4-11 xenograft mouse model, a once-daily dose of compound 33 at 10 mg/kg for 18 days led to complete tumor regression without obvious toxicity. Western blot and immunohistochemical analyses were performed to determine the mechanism of action of compound 33.

Synthesis of new coumarin compounds and its hypoglycemic activity and structure-activity relationship

Novel coumarin compounds were designed and synthesized by combining the active moieties of hypoglycemic drugs. The coumarin compounds were made by sulfanilamide with isocynate, the intermediate sulfanilamide was formed from coumarin by chlorosulfonated and aminated. These targeted compounds were characterized by FT-IR, 1H NMR and MS spectra and their hypoglycemic activities were evaluated in mice. The preliminary results showed that some compounds exhibited evident hypoglycemic effect (P > 0.01, CMC-Na as negative control). The relationship between these compounds structure with their hypoglycemic activities were studied in order to design new antidiabetic agents.

Synthesis of aryl urea derivatives from aryl amines and aryl isocyanates

The present study describes the synthesis of novel diaryl urea derivatives derived from aryl amine and aryl isocyanates. The synthesized compounds are analogs of sorafenib [4-[4-[[[4-chloro-3-(trifluoromethyl)phenyl]amino]carbonyl] amino]phenoxy]-N-methylpyridine-2- carboxamide] having potential antiproliferative activity.

Parasiticidal new substituted thienopyranones

Parasiticidal new substituted thienopyranones of the formula STR1 in which X represents O or S, R1 and R2 independently of one another represent hydrogen, halogen, CN, NO2, alkyl, aralkyl, aryl, alkylcarbonyl or alkoxycarbonyl, or, together with the adjacent C atoms, form a carbocyclic ring which is optionally interrupted by heteroatoms, R3 represents optionally substituted alkyl or phenyl, R4 represents hydrogen or alkyl, R3 and R4, together with the adjacent nitrogen atom, represent a heterocyclic 5- or 6-membered ring. Some of the intermediates for making them are also new.